Production (Stage)
Silence Therapeutics plc
SLN
$5.19
$0.193.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.93M | 43.49M | 19.93M | 21.99M | 32.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.93M | 43.49M | 19.93M | 21.99M | 32.63M |
| Cost of Revenue | 9.26M | 12.00M | 11.18M | 9.60M | 9.82M |
| Gross Profit | 18.68M | 31.49M | 8.76M | 12.39M | 22.82M |
| SG&A Expenses | 28.42M | 27.37M | 25.77M | 24.76M | 24.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.33M | 92.24M | 81.65M | 70.46M | 72.33M |
| Operating Income | -71.40M | -48.75M | -61.72M | -48.47M | -39.70M |
| Income Before Tax | -70.44M | -43.98M | -71.57M | -45.82M | -38.85M |
| Income Tax Expenses | 2.54M | 2.78M | 3.00M | 4.04M | 4.40M |
| Earnings from Continuing Operations | -72.97 | -46.76 | -74.57 | -49.86 | -43.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.97M | -46.76M | -74.57M | -49.86M | -43.25M |
| EBIT | -71.40M | -48.75M | -61.72M | -48.47M | -39.70M |
| EBITDA | -70.81M | -48.15M | -61.13M | -47.87M | -39.10M |
| EPS Basic | -4.66 | -3.00 | -5.01 | -3.60 | -3.42 |
| Normalized Basic EPS | -0.94 | -0.59 | -0.98 | -0.68 | -0.65 |
| EPS Diluted | -4.66 | -3.00 | -5.01 | -3.60 | -3.42 |
| Normalized Diluted EPS | -0.94 | -0.59 | -0.98 | -0.68 | -0.65 |
| Average Basic Shares Outstanding | 188.26M | 184.99M | 176.68M | 166.92M | 156.35M |
| Average Diluted Shares Outstanding | 62.75M | 61.66M | 58.89M | 55.64M | 52.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |